SB 600: Health care coverage: fertility preservation.
- Session Year: 2019-2020
- House: Senate
- Latest Version Date: 2019-10-12
Existing law, the Knox-Keene Health Care Service Plan Act of 1975, provides for the licensure and regulation of health care service plans by the Department of Managed Health Care and makes a willful violation of the act a crime.
Existing law requires every health care service plan contract to provide enrollees with basic health care services, except as specified. Existing law defines basic health care services to include, among other things, physician services and hospital inpatient and ambulatory care services. Existing law requires specified group health care service plan contracts issued, amended, or renewed on or after January 1, 1990, to offer coverage for the treatment of infertility, as defined, except in vitro fertilization.
This bill would clarify that, when a covered treatment may cause iatrogenic infertility to an enrollee, standard fertility preservation services are a basic health care service and are not within the scope of coverage for infertility treatment, as described above. The bill would state that these provisions are declaratory of existing law. The bill would state that these provisions do not apply to Medi-Cal managed care health care service plan contracts or any entity that contracts with the State Department of Health Care Services to deliver health care services pursuant to the Medi-Cal program.
(a)When a covered treatment may directly or indirectly cause iatrogenic infertility, standard fertility preservation services are a basic health care service, as defined in subdivision (b) of Section 1345, and are not within the scope of coverage for the treatment of infertility for the purposes of Section 1374.55.
(b)For purposes of this section, the following definitions apply:
(1)Iatrogenic infertility means infertility caused directly or indirectly by surgery, chemotherapy, radiation, or other medical treatment.
(2)May directly or indirectly cause means medical treatment with a possible side effect of infertility, as established by the American Society of Clinical Oncology or the American Society for Reproductive Medicine.
(3)Standard fertility preservation services means procedures consistent with the established medical practices and professional guidelines published by the American Society of Clinical Oncology or the American Society for Reproductive Medicine.
(c)This section does not apply to Medi-Cal managed care health care service plan contracts or any entity that enters into a contract with the State Department of Health Care Services for the delivery of health care services pursuant to Chapter 7 (commencing with Section 14000), Chapter 8 (commencing with Section 14200), Chapter 8.75 (commencing with Section 14591), or Chapter 8.9 (commencing with Section 14700) of Part 3 of Division 9 of the Welfare and Institutions Code.
SEC. 2.The addition of Section 1374.551 to the Health and Safety Code by this act does not constitute a change in, but is declaratory of, existing law.
|
Date
|
Status
|
|---|---|
| Oct 12, 2019 | Chaptered by Secretary of State. Chapter 853, Statutes of 2019. |
| Oct 12, 2019 | Approved by the Governor. |
| Sep 19, 2019 | Enrolled and presented to the Governor at 3 p.m. |
| Sep 11, 2019 | Assembly amendments concurred in. (Ayes 38. Noes 0.) Ordered to engrossing and enrolling. |
| Sep 9, 2019 | In Senate. Concurrence in Assembly amendments pending. |
| Sep 9, 2019 | Read third time. Passed. Ordered to the Senate. |
| Sep 5, 2019 | Read third time and amended. |
| Sep 3, 2019 | Read second time. Ordered to third reading. |
| Aug 30, 2019 | From committee: Do pass. (Ayes 13. Noes 1.) (August 30). |
| Aug 14, 2019 | August 14 set for first hearing. Placed on APPR. suspense file. |
| Jul 10, 2019 | From committee: Do pass and re-refer to Com. on APPR. (Ayes 10. Noes 0.) (July 9). Re-referred to Com. on APPR. |
| May 30, 2019 | Referred to Com. on HEALTH. |
| May 22, 2019 | In Assembly. Read first time. Held at Desk. |
| May 21, 2019 | Read third time. Passed. (Ayes 38. Noes 0.) Ordered to the Assembly. |
| May 16, 2019 | From committee: Do pass. (Ayes 4. Noes 2.) (May 16). |
| May 14, 2019 | Set for hearing May 16. |
| May 13, 2019 | May 13 hearing: Placed on APPR. suspense file. |
| May 3, 2019 | Set for hearing May 13. |
| Apr 30, 2019 | Read second time and amended. Re-referred to Com. on APPR. |
| Apr 29, 2019 | From committee: Do pass as amended and re-refer to Com. on APPR. (Ayes 8. Noes 0.) (April 24). |
| Mar 22, 2019 | Set for hearing April 24. |
| Mar 14, 2019 | Referred to Com. on HEALTH. |
| Feb 25, 2019 | Read first time. |
| Feb 25, 2019 | From printer. May be acted upon on or after March 27. |
| Feb 22, 2019 | Introduced. To Com. on RLS. for assignment. To print. |
|
Date
|
Description
|
Location
|
Votes
|
|
|---|---|---|---|---|
| Sep 11, 2019 | Unfinished Business SB600 Portantino Concurrence | Senate Floor |
Passed |
|
| Sep 9, 2019 | SB 600 Portantino Senate Third Reading By Wicks | Assembly Floor |
Passed |
|
| Aug 30, 2019 | Do pass. | Assembly Standing Committee on Appropriations |
Passed |
|
| Jul 9, 2019 | Do pass and be re-referred to the Committee on [Appropriations] | Assembly Standing Committee on Health |
Passed |
|
| May 21, 2019 | Senate 3rd Reading SB600 Portantino | Senate Floor |
Passed |
|
| May 16, 2019 | Do pass | Senate Standing Committee on Appropriations |
Passed |
|
| May 13, 2019 | Placed on suspense file | Senate Standing Committee on Appropriations |
Passed |
|
| Apr 24, 2019 | Do pass as amended, but first amend, and re-refer to the Committee on [Appropriations] | Senate Standing Committee on Health |
Passed |
This list shows positions taken on this bill by organizations on the date displayed, which is linked to the original source.
Positions by individuals are not included.
Office of Senate Floor Analyses (916) 651-1520 Fax: (916) 327-4478 | SB 600 |
UNFINISHED BUSINESS
Bill No: SB 600
Amended: 9/5/19
SENATE HEALTH COMMITTEE: 8-0, 4/24/19
AYES: Pan, Stone, Durazo, Hurtado, Leyva, Mitchell, Monning, Rubio
NO VOTE RECORDED: Grove
SENATE APPROPRIATIONS COMMITTEE: 4-2, 5/16/19
AYES: Portantino, Bradford, Hill, Wieckowski
NOES: Bates, Jones
SENATE FLOOR: 38-0, 5/21/19
AYES: Allen, Archuleta, Atkins, Bates, Beall, Borgeas, Bradford, Caballero, Chang, Dodd, Durazo, Galgiani, Glazer, Grove, Hertzberg, Hill, Hueso, Hurtado, Jackson, Jones, Leyva, McGuire, Mitchell, Monning, Moorlach, Morrell, Nielsen, Pan, Portantino, Roth, Rubio, Skinner, Stern, Stone, Umberg, Wieckowski, Wiener, Wilk
ASSEMBLY FLOOR: 56-2, 9/9/19 - See last page for vote
SUBJECT: Health care coverage: fertility preservation
SOURCE: Alliance for Fertility Preservation
American Society for Reproductive Medicine
Fertile Action
DIGEST:
- This bill states that standard fertility preservation services are covered as basic health services when a covered treatment may directly or indirectly cause iatrogenic infertility.
Assembly Amendments narrow the bill by exempting Medi-Cal managed care plans and insurance policies and clarifying that these services are basic health care services with respect to health plans.
Existing law:
- Establishes the Department of Managed Health Care (DMHC) to regulate health plans under the Knox-Keene Health Care Services Plan Act of 1975; the California Department of Insurance (CDI) to regulate health and other insurers;; and, the Department of Health Care Services (DHCS) to administer the Medi-Cal program. [HSC §1340, et seq., INS §106, et seq., and WIC §14000, et seq.]
- Defines “basic health care services” to include, in part, physician services, including consultation and referral; hospital inpatient services and ambulatory care services; diagnostic laboratory and therapeutic radiologic services; and, emergency health care services, including ambulance and ambulance transport services and out-of-area coverage. Basic health care services includes ambulance and ambulance transport services provided through the 911 emergency response system. [HSC §1345]
- Requires most health plan contracts and health insurance policies to offer group coverage for the treatment of infertility, except in vitro fertilization (IVF), as defined. This does not apply to health maintenance organizations with group contract holders with less than 20 employees to whom the plan is offered. [HSC §1374.55 and INS §10119.6]
- Defines “infertility” as either the presence of a demonstrated condition recognized by a licensed physician and surgeon as a cause of infertility, or, the inability to conceive a pregnancy or to carry a pregnancy to live birth after a year or more of regular sexual relations without contraception. [HSC §1374.55 and INS §10119.6]
- Defines “treatment for infertility” as procedures consistent with established medical practices in the treatment of infertility by licensed physicians and surgeons including, but not limited to, diagnosis, diagnostic tests, medication, surgery, and gamete intrafallopian transfer. [HSC §1374.55 and INS §10119.6]
This bill:
- Requires that when a covered treatment may directly or indirectly cause iatrogenic infertility, standard fertility preservation services are a basic health care service, as defined, and are not within the scope of coverage for the treatment of infertility, as specified.
- Defines “Iatrogenic infertility” to mean infertility caused directly or indirectly by surgery, chemotherapy, radiation, or other medical treatment.
- States that 1) and 2) above are declaratory of existing law.
- Exempts Medi-Cal managed care plans, as specified, from this bill.
Background
- Iatrogenic infertility. Iatrogenic infertility is medically induced infertility caused by a medical intervention used to treat a primary disease or condition. Iatrogenic infertility is typically caused by cancer treatments, such as radiation and chemotherapy (gonadotoxic treatments) or surgical removal of reproductive organs. Less frequently, fertility is compromised by treatments for autoimmune disorders such as systemic lupus erythematosus, rheumatoid arthritis, or Crohn’s disease. Autoimmune conditions sometimes require gonadotoxic or surgical treatments; individuals with gender and sex diversity such as individuals who are transgender may also undergo gonadotoxic treatments. According to data from the California Cancer Registry, more than 8,000 Californians of reproductive age (2,950 males and 5,701 females aged 10 to 44 years), regardless of insurance status, are diagnosed annually with a cancer whose treatments are likely to result in iatrogenic infertility. The increased risk of iatrogenic infertility for women is due to the high incidence of breast cancer.
- Independent Medical Reviews (IMRs). The author’s office has provided the Senate Health Committee with copies of five IMR findings that overturned decisions of health plans with respect to reimbursement for fertility preservation services. CHBRP reviewed the state’s IMR determinations and found three determinations related to fertility preservation. The decision most relevant to this bill involved a 33-year old woman who requested embryo cryopreservation following a breast cancer diagnosis. The decision noted that embryo cryopreservation is the best established method of fertility preservation. The IMR decision ruled that this was an appropriate therapy, and the enrollee’s only option to preserve fertility; the health plan’s decision was overturned. Another decision involved an enrollee request for a fertility specialist consultation and potential egg retrieval and use of a surrogate. Partially due to the patient’s age, the IMR deemed that the patient’s request was medically necessary, and the health plan decision was overturned. The third decision involved an enrollee undergoing gender transition (aged 11–20 years) whose parents requested oocyte cryopreservation. The reviewers noted it was not clear whether the patient had expressed a desire to preserve his fertility, and thus, the reviewers deemed that the service was not medically necessary for the enrollees’ treatment. The IMR decision upheld the health plan’s decision.
- DMHC letters. The author’s office provided the Senate Health Committee with a letter from DMHC to a plan enrollee that indicates that the enrollee’s plan covered fertility preservation services as basic health care services that are required under California law, and DMHC directed the plan to reimburse the enrollee for the reasonable cost. The plan declined to comply and the matter was referred to the DMHC Office of Enforcement for further investigation, including possible administrative penalties or fines. Another letter from DMHC provided by the author’s office, dated December 21, 2018, states that fertility preservation is a particular complicated issue, due to its association with standard infertility treatment, which is statutorily exempt as a required basic health care service and often is not covered by health plans except under a separate rider. The letter also states that health plans licensed under the Knox-Keene Act must provide medically necessary fertility preservation services as part of the law’s long standing requirement that health plans cover all basic health care services. DMHC has initiated enforcement action, and DMHC no longer approves plan documentation that purports to exclude medically necessary fertility preservation. DMHC has communicated this to health plans and has conducted individual plan-by-plan conferences to explain DMHC’s position and expectation for compliance. In addition, DMHC does not generally attempt to identify a specific medical standard of care as a covered basic health care service and that by design, basic health care services are flexible as the medical standard evolves. Furthermore, what constitutes medically necessary basic health care services can vary based on the unique circumstances of the patient.
Comments
According to the author, despite DMHC repeatedly overturning health plan denials of fertility preservation, denials continually occur and three health plans have blatantly defied the DMHC’s order to pay specific claims. The confusion in coverage forces many patients to forego fertility preservation that they, in fact, have coverage for. They simply do not have time to delay their life-saving cancer treatments to challenge denials of coverage. In the face of these high costs, some patients compromise their treatment decisions in attempt to protect their fertility. Forcing patients into these kinds of decisions may lead to worse medical outcomes.
FISCAL EFFECT: Appropriation: No Fiscal Com.: Yes Local: No
According to the Assembly Appropriations Committee:
- According to the Department of Health Care Services, this bill would apply to Medi-Cal managed care, which does not currently cover these services. Costs to provide services to the Medi-Cal population would likely be in the millions of dollars annually (GF/federal). GF costs would vary depending on whether federal approval was obtained and whether the state share of costs would be 50% or 90%.
- Costs of approximately $270,000 annually to CalPERS health plans (GF/federal/special/ local).
- The California Health Benefit Review Program (CHBRP) reports the following private market costs:
- Increased employer-funded premium costs in the private insurance market of approximately $5.8 million.
- Increased premium expenditures by employees and individuals purchasing insurance of $2.2 million, as well as a reduction of $1.5 million in enrollee out-of-pocket costs.
- Costs to the California Department of Insurance (Insurance Fund) and Department of Managed Health Care (Managed Care Fund) to verify compliance are expected to be minor and absorbable.
Alliance for Fertility Preservation (co-source)
American Society for Reproductive Medicine (co-source)
Fertile Action (co-source)
American Cancer Society Cancer Action Network
American Civil Liberties Union of California
American College of Obstetricians and Gynecologists District IX
American Society of Clinical Oncology
Association of Northern California Oncologists
California Chronic Care Coalition
California CryoBank
Citizen’s for Choice
Medical Oncology Association of Southern California
Miller Children’s Hospital/ UCLA Dept of Pediatrics Hematology Oncology
National Center for Lesbian Rights
Nevada Citizens for Choice
RESOLVE: The National Infertility Association
Teen Cancer America
Triage Cancer
Ulman Foundation
USC Fertility
Young Survival Coalition
America’s Health Insurance Plans
Association of California Life and Health Insurance Companies
California Association of Health Plans
California Chamber of Commerce
ARGUMENTS IN SUPPORT: The American Society for Reproductive Medicine (ASRM) writes, the relatively high out-of-pocket costs (especially for women) for patients paying cash makes treatment unaffordable for many patients if they don’t believe they have coverage. Coupled with the short window of opportunity for undergoing these procedures (between diagnosis and commencement of treatment), it is crucial patients know of their options up front. ASRM finds that some patients choose less than recommended treatment for their underlying condition in an attempt to preserve their fertility if they cannot obtain fertility preservation services. This can lead to worse and more expensive outcomes. While the coverage portion of this bill is declaratory of existing law, ASRM appreciates the addition of a provision regarding medical necessity decisions. Typically the health plan or insurer is charged with making decisions as to whether a particular case meets the criteria of being medically necessary. Due to a pattern of delay and outright refusals to pay claims, even when ordered to by DMHC (regulating HMOs), the step of removing that decision from the health plans and insurers, while drastic, appears necessary under the circumstances. This bill will ensure that all patients who undergo medically necessary treatments such as chemotherapy, radiation, and certain surgeries are also able to access standard fertility preservation treatments more readily in order to protect their future ability to have biologic children. According to the American Cancer Society Action Cancer Network the cost to preserve fertility is not a covered option for the majority of cancer patients, even though fertility loss occurs as a direct consequence of their treatment. As health plans currently cover reconstructive surgery for breast cancer patients, they should similarly reserve the option of fertility preservation for patients undergoing chemotherapy and radiation.
ARGUMENTS IN OPPOSITION: The California Association of Health Plans opposes this bill indicating that that it falsely states the new coverage requirement is “declaratory of existing law” because plans and the state could incur significant litigation risk, including but not unlimited to class action lawsuits, inconsistent rulings, and punitive damages. These costs will fall on consumers. This bill excludes Medi-Cal from the new benefit and leaves unresolved clinical, ethical and operational issues and will create confusion.
ASSEMBLY FLOOR: 56-2, 9/9/19
AYES: Aguiar-Curry, Arambula, Bauer-Kahan, Berman, Bloom, Boerner Horvath, Bonta, Burke, Calderon, Carrillo, Cervantes, Chau, Chiu, Chu, Cooley, Diep, Eggman, Friedman, Gabriel, Eduardo Garcia, Gipson, Gloria, Gonzalez, Gray, Holden, Irwin, Jones-Sawyer, Kalra, Kamlager-Dove, Levine, Limón, Low, Maienschein, McCarty, Medina, Melendez, Mullin, Nazarian, O'Donnell, Petrie-Norris, Quirk, Quirk-Silva, Ramos, Reyes, Luz Rivas, Robert Rivas, Rodriguez, Blanca Rubio, Salas, Santiago, Mark Stone, Ting, Weber, Wicks, Wood, Rendon
NOES: Brough, Lackey
NO VOTE RECORDED: Bigelow, Chen, Choi, Cooper, Cunningham, Daly, Flora, Fong, Frazier, Gallagher, Cristina Garcia, Grayson, Kiley, Mathis, Mayes, Muratsuchi, Obernolte, Patterson, Smith, Voepel, Waldron
Prepared by: Teri Boughton / HEALTH / (916) 651-4111
9/10/19 11:20:04
**** END ****
SENATE THIRD READING
STR Bill Id:SB 600
Author:(Portantino)
As Amended Ver:September 5, 2019
Majority vote
SUMMARY:
Clarifies that standard fertility preservation services, when a covered treatment may directly or indirectly cause iatrogenic infertility, are a basic health care service, as defined in existing law, and are not within the scope of coverage for the treatment of infertility, as specified. Exempts Medi-Cal managed care health care service plan contracts or any entity that enters into a contract with the Department of Health Care Services for the delivery of health care services.
Major Provisions
COMMENTS:
Fertility Preservation as a Covered Benefit. According to the Department of Managed Health Care (DMHC), fertility preservation service is a type of procedure used to help keep a person's ability to have children. A fertility preservation procedure is done before a medical treatment that may cause infertility, such as radiation therapy or chemotherapy. Examples of fertility preservation procedures include sperm banking, egg freezing, in vitro fertilization with embryo freezing, and certain types of surgery for cervical and ovarian cancer. All of the above fertility preservation services require consultations (physician services), lab work (diagnostic laboratory services), outpatient surgical procedures (ambulatory care services), and preventative health services, all of which are defined as basic health care services.
Pending DMHC Case. On April 24, 2019, the DMHC issued an Order to Cease and Desist to one of its health plan licensees. This Order declared that the health plan failed to provide basic health care services as set forth in the Evidence of Coverage (EOC) and acted at variance to its EOCs in denying fertility preservation services under the "Infertility Services" and "Fertility Services" exclusions. The DMHC prohibited the health plan from using any "Infertility Services" or "Fertility Services" exclusion to deny fertility preservation services when medically necessary to prevent iatrogenic infertility; denying fertility preservation services for enrollees at risk of iatrogenic infertility as not covered and/or excluded under an enrollee's EOC, or on any other basis except for medical necessity; instructing and/or suggesting in any way to its contracted providers and medical groups that fertility preservation services when medically necessary to prevent iatrogenic infertility are not covered; putting any language into an EOC that would indicate that fertility preservation services when medically necessary to prevent iatrogenic infertility are not covered and/or are excluded; and marketing, selling or advertising any fertility preservation riders to large group purchasers.
The health plan subject to the above Order filed a response, indicating that the health plan was under no legal obligation to provide coverage for fertility preservation services to its members, other than those members who purchased the health plan's optional fertility preservation services rider. The health plan provided support of its position, including, but not limited to: lack of statute that mandates coverage for fertility preservation services; the Legislature introduced bills mandating coverage for fertility preservation services; and, lack of regulation that mandates coverage for fertility preservation services.
According to the DMHC, this enforcement matter is ongoing.
According to the Author:
Despite the DMHC repeatedly overturning health plan denials of fertility preservation, denials continually occur and three health plans have blatantly defied the DMHC's order to pay specific claims. The confusion in coverage forces many patients to forego fertility preservation that they, in fact, have coverage for. They simply do not have time to delay their life-saving cancer treatments to challenge denials of coverage. In the face of these high costs, some patients compromise their treatment decisions in attempts to protect their fertility. Forcing patients into these kinds of decisions may lead to worse medical outcomes.
Arguments in Support:
According to the American Society for Reproductive Medicine (ASRM), cosponsors of this bill, other conditions requiring similar therapies (sickle cell anemia, lupus, and thalassemia for example) can also compromise fertility, in addition to cancer patients. However, it is not always clear as to whether these procedures are covered insurance options for the majority of patients. The lack of clarity in the coverage is likely that few are (understandably) sophisticated enough to know the difference between fertility preservation and "infertility" coverage. ASRM states that coupled with the short window of opportunity for undergoing these procedures (between diagnosis and commencement of treatment), it is crucial patients know of their options up front.
Arguments in Opposition:
The California Chamber of Commerce (CCC) contends that it is unclear what "standard" fertility services include and how many attempts are required under this bill. Additionally, it is unclear whether the bill is focused on medical treatment such as chemotherapy or other cancer related treatment or if the "treatment' would also include surgery or medication for non-cancer related treatment. Fertility preservation services are very costly, and the broad language of the bill would likely result in significant added costs to all enrollee premiums, not just those who use the services. According to CCC, this bill also prohibits any review of medical necessity by a health plan or insurer. Not only does this eliminate health plan review of this specific issue, it eliminates cost containment measures that benefit all enrollees. The Department of Finance is opposed to this bill because, to the extent that health plan contracts and insurance policies are not currently providing the fertility services, the bill results in significant General Fund (GF) costs, potentially in the tens of millions of dollars, not included in the Budget Act of 2019.
FISCAL COMMENTS:
According to the Assembly Appropriations Committee, costs to provide services to the Medi-Cal population would likely be in the millions of dollars annually (GF/federal). Costs of approximately $270,000 annually to CalPERS health plans (GF/federal/special/local). Private market costs of $8 million as well as a reduction of $1.5 million in enrollee out-of-pocket costs. Costs to the California Department of Insurance (Insurance Fund) and DMHC (Managed Care Fund) to verify compliance are expected to be minor and absorbable. This bill was recently amended to delete provisions as it relates to Medi-Cal and the Department of Insurance.
VOTES:
SENATE FLOOR: 38-0-0
YES: Allen, Archuleta, Atkins, Bates, Beall, Borgeas, Bradford, Caballero, Chang, Dodd, Durazo, Galgiani, Glazer, Grove, Hertzberg, Hill, Hueso, Hurtado, Jackson, Jones, Leyva, McGuire, Mitchell, Monning, Moorlach, Morrell, Nielsen, Pan, Portantino, Roth, Rubio, Skinner, Stern, Stone, Umberg, Wieckowski, Wiener, Wilk
ASM HEALTH: 10-0-5
YES: Wood, Aguiar-Curry, Bonta, Carrillo, Limón, McCarty, Nazarian, Ramos, Rodriguez, Santiago
ABS, ABST OR NV: Mayes, Bigelow, Burke, Flora, Waldron
ASM APPROPRIATIONS: 14-1-3
YES: Gonzalez, Bloom, Bonta, Calderon, Carrillo, Chau, Eggman, Fong, Gabriel, Eduardo Garcia, Maienschein, Petrie-Norris, Quirk, Robert Rivas
NO: Bigelow
ABS, ABST OR NV: Brough, Diep, Obernolte
UPDATED:
VERSION: September 5, 2019
CONSULTANT: Kristene Mapile / HEALTH / (916) 319-2097 FN: 0001786
SENATE THIRD READING
STR Bill Id:SB 600
Author:(Portantino)
As Amended Ver:April 30, 2019
Majority vote
SUMMARY:
Requires an individual or group health care service plan (health plan) contract or health insurance policy, as specified, to include coverage for standard fertility preservation services when a medically necessary treatment may cause iatrogenic infertility to an enrollee or insured. States that the provisions of this bill are declaratory of existing law. Adds to the Medi-Cal schedule of benefits, standard fertility preservation services when a medically necessary treatment may cause iatrogenic infertility to a beneficiary.
Major Provisions
COMMENTS:
Fertility Preservation as a Covered Benefit. According to the Department of Managed Health Care (DMHC), fertility preservation service is a type of procedure used to help keep a person's ability to have children. A fertility preservation procedure is done before a medical treatment that may cause infertility, such as radiation therapy or chemotherapy. Examples of fertility preservation procedures include sperm banking, egg freezing, in vitro fertilization with embryo freezing, and certain types of surgery for cervical and ovarian cancer. All of the above fertility preservation services require consultations (physician services), lab work (diagnostic laboratory services), outpatient surgical procedures (ambulatory care services), and preventative health services, all of which are defined as basic health care services.
Pending DMHC Case. On April 24, 2019, the DMHC issued an Order to Cease and Desist to one of its health plan licensees. This Order declared that the health plan failed to provide basic health care services as set forth in the Evidence of Coverage (EOC) and acted at variance to its EOCs in denying fertility preservation services under the "Infertility Services" and "Fertility Services" exclusions. The DMHC prohibited the health plan from using any "Infertility Services" or "Fertility Services" exclusion to deny fertility preservation services when medically necessary to prevent iatrogenic infertility; denying fertility preservation services for enrollees at risk of iatrogenic infertility as not covered and/or excluded under an enrollee's EOC, or on any other basis except for medical necessity; instructing and/or suggesting in any way to its contracted providers and medical groups that fertility preservation services when medically necessary to prevent iatrogenic infertility are not covered; putting any language into an EOC that would indicate that fertility preservation services when medically necessary to prevent iatrogenic infertility are not covered and/or are excluded; and marketing, selling or advertising any fertility preservation riders to large group purchasers.
The health plan subject to the above Order filed a response, indicating that the health plan was under no legal obligation to provide coverage for fertility preservation services to its members, other than those members who purchased the health plan's optional fertility preservation services rider. The health plan provided support of its position, including, but not limited to: lack of statute that mandates coverage for fertility preservation services; the Legislature introduced bills mandating coverage for fertility preservation services; and, lack of regulation that mandates coverage for fertility preservation services.
According to the DMHC, this enforcement matter is ongoing.
According to the Author:
Despite the DMHC repeatedly overturning health plan denials of fertility preservation, denials continually occur and three health plans have blatantly defied the DMHC's order to pay specific claims. The confusion in coverage forces many patients to forego fertility preservation that they, in fact, have coverage for. They simply do not have time to delay their life-saving cancer treatments to challenge denials of coverage. In the face of these high costs, some patients compromise their treatment decisions in attempts to protect their fertility. Forcing patients into these kinds of decisions may lead to worse medical outcomes.
Arguments in Support:
According to the American Society for Reproductive Medicine (ASRM), cosponsors of this bill, other conditions requiring similar therapies (sickle cell anemia, lupus, and thalassemia for example) can also compromise fertility, in addition to cancer patients. However, it is not always clear as to whether these procedures are covered insurance options for the majority of patients. The lack of clarity in the coverage is likely that few are (understandably) sophisticated enough to know the difference between fertility preservation and "infertility" coverage. ASRM states that coupled with the short window of opportunity for undergoing these procedures (between diagnosis and commencement of treatment), it is crucial patients know of their options up front.
Arguments in Opposition:
The California Chamber of Commerce (CCC) contends that it is unclear what "standard" fertility services include and how many attempts are required under this bill. Additionally, it is unclear whether the bill is focused on medical treatment such as chemotherapy or other cancer related treatment or if the "treatment' would also include surgery or medication for non-cancer related treatment. Fertility preservation services are very costly, and the broad language of the bill would likely result in significant added costs to all enrollee premiums, not just those who use the services. According to CCC, this bill also prohibits any review of medical necessity by a health plan or insurer. Not only does this eliminate health plan review of this specific issue, it eliminates cost containment measures that benefit all enrollees. The Department of Finance is opposed to this bill because, to the extent that health plan contracts and insurance policies are not currently providing the fertility services, the bill results in significant General Fund (GF) costs, potentially in the tens of millions of dollars, not included in the Budget Act of 2019.
FISCAL COMMENTS:
According to the Assembly Appropriations Committee, costs to provide services to the Medi-Cal population would likely be in the millions of dollars annually (GF/federal). Costs of approximately $270,000 annually to CalPERS health plans (GF/federal/special/local). Private market costs of $8 million as well as a reduction of $1.5 million in enrollee out-of-pocket costs. Costs to the California Department of Insurance (Insurance Fund) and DMHC (Managed Care Fund) to verify compliance are expected to be minor and absorbable.
VOTES:
SENATE FLOOR: 38-0-0
YES: Allen, Archuleta, Atkins, Bates, Beall, Borgeas, Bradford, Caballero, Chang, Dodd, Durazo, Galgiani, Glazer, Grove, Hertzberg, Hill, Hueso, Hurtado, Jackson, Jones, Leyva, McGuire, Mitchell, Monning, Moorlach, Morrell, Nielsen, Pan, Portantino, Roth, Rubio, Skinner, Stern, Stone, Umberg, Wieckowski, Wiener, Wilk
ASM HEALTH: 10-0-5
YES: Wood, Aguiar-Curry, Bonta, Carrillo, Limón, McCarty, Nazarian, Ramos, Rodriguez, Santiago
ABS, ABST OR NV: Mayes, Bigelow, Burke, Flora, Waldron
ASM APPROPRIATIONS: 14-1-3
YES: Gonzalez, Bloom, Bonta, Calderon, Carrillo, Chau, Eggman, Fong, Gabriel, Eduardo Garcia, Maienschein, Petrie-Norris, Quirk, Robert Rivas
NO: Bigelow
ABS, ABST OR NV: Brough, Diep, Obernolte
UPDATED:
VERSION: April 30, 2019
CONSULTANT: Kristene Mapile / HEALTH / (916) 319-2097 FN: 0001685
Date of Hearing: August 14, 2019
ASSEMBLY COMMITTEE ON APPROPRIATIONS
Lorena Gonzalez, Chair
SBPCA Bill Id:SB 600
Author:(Portantino) – As Amended Ver:April 30, 2019
Policy Committee: | Health | Vote: | 10 - 0 |
Urgency: No State Mandated Local Program: No Reimbursable: No
SUMMARY:
This bill mandates health plans, insurers, and Medi-Cal to cover fertility preservation services, as specified, when a medically necessary treatment may directly or indirectly cause “iatrogenic” infertility (infertility induced by a medical treatment).
It also indicates the bill’s mandate on health plans and insurers to cover the benefit does not constitute a change in, but is declaratory of, existing law.
FISCAL EFFECT:
- According to the Department of Health Care Services, this bill would apply to Medi-Cal managed care, which does not currently cover these services. Costs to provide services to the Medi-Cal population would likely be in the millions of dollars annually (GF/federal). GF costs would vary depending on whether federal approval was obtained and whether the state share of costs would be 50% or 90%.
- Costs of approximately $270,000 annually to CalPERS health plans (GF/federal/special/ local).
- The California Health Benefit Review Program (CHBRP) reports the following private market costs:
- Increased employer-funded premium costs in the private insurance market of approximately $5.8 million.
- Increased premium expenditures by employees and individuals purchasing insurance of $2.2 million, as well as a reduction of $1.5 million in enrollee out-of-pocket costs.
- Costs to the California Department of Insurance (Insurance Fund) and Department of Managed Health Care (Managed Care Fund) to verify compliance are expected to be minor and absorbable.
COMMENTS:
- Purpose. According to the author, the DMHC has repeatedly overturned health plan denials of fertility preservation and yet plans have blatantly defied the DMHC’s order to pay specific claims. The author states fertility preservation is indeed covered under existing law and this bill is needed to clarify that fact. The author notes in absence of coverage for fertility preservation, worse medical outcomes may result if patients compromise their treatment decisions in attempts to protect their fertility.
- Background and Prior Legislative Attempts. According to CHBRP, iatrogenic infertility is medically induced infertility caused by a medical intervention used to treat a primary disease or condition. Iatrogenic infertility is typically caused by cancer treatments, such as radiation and chemotherapy or surgical removal of reproductive organs. Approximately 90% of iatrogenic infertility is caused by cancer treatment.
Several similar prior bills have been introduced on this topic. AB 428 (Portantino), of the 2011-12 Legislative Session and SB 172 (Portantino), of the 2017-18 Legislative Session were both held on the Senate Appropriations Committee suspense file. AB 912 (Quirk-Silva), of the 2013-14 Legislative Session. AB 912 was vetoed by then Governor Brown, who stated we should not consider mandating additional benefits until we implement the comprehensive package of reforms that are required by the federal Affordable Care Act.
- DMHC Position and Enforcement Action. Health plans are required to cover a set of “basic health care services.”
Based on DMHC’s interpretation that the standard of care had changed sufficiently to include iatrogenic fertility preservation services as a basic health care service, the department notified Kaiser Foundation Health Plan, Inc. (Kaiser) throughout 2018 that these services must be covered. On May 2019, DMHC filed a cease and desist order, ordering Kaiser to cover fertility preservation when medically necessary for enrollees at risk of iatrogenic infertility.
DMHC notes in the order that in late December 2017, DMHC mistakenly approved Kaiser’s request to sell a Fertility Preservation Rider to two large employer groups (a rider is additions of non-mandated coverage that are sold as supplemental to a health plan). The rider should only have been approved if the services were supplemental to basic health care services and not otherwise covered.
- Kaiser Response and Related Writ of Mandate. In response to DMHC’s cease and desist order, Kaiser argues the following in its defense:
- DMHC’s interpretation constitutes an underground regulation.
- DMHC’s interpretation is inconsistent with years of prior regulatory conduct and inconsistent with legislative history and three attempts to mandate coverage since 2011 that were not enacted into law. Kaiser points out DMHC’s approval of fertility preservation riders as evidence fertility preservation was not required to be covered as a basic health care service.
- It would be inequitable to require Kaiser to provide coverage when the cost of such coverage was not factored into the plan’s pricing and when there exist many important unresolved implementation issues (such as the length of time a plan is liable to maintain frozen eggs).
In a separate action, on July 8, 2019, the trade group representing health plans, the California Association of Health Plans (CAHP), filed a writ of mandate and complaint for declaratory and injunctive relief in the County of Los Angeles Superior Court. CAHP seeks one of the following remedies: either DMHC reverse its mandate to provide coverage of fertility preservation services to enrollees at risk of iatrogenic infertility and henceforth treat such coverage as optional, or DMHC issue regulations pursuant to the Administrative Procedures Act.
- Implications of this Legislation. This bill would not only require coverage, but would state the private coverage requirement is declaratory of existing law, essentially siding with DMHC’s legal interpretation. The statement that the bill is declaratory of existing law is inaccurate with respect to some policies regulated by CDI and is the subject of litigation with respect to policies regulated by DMHC, as noted above.
- Support. This bill is co-sponsored by American Society For Reproductive Medicine,
Alliance For Fertility Preservation, and Fertile Action and supported by a number of reproductive health, medical, cancer and infertility advocacy groups. - Oppose Unless Amended. The California Association of Health Plans and the Association of California Life and Health Insurance Companies request the following amendments:
- Remove all references to the retroactivity of the fertility preservation mandate.
- Clarify the definition of medical necessity and define “iatrogenic infertility.”
- Establish a timeframe for storage of reproductive material.
- Require use of evidenced-based standards of care when determining iatrogenic infertility.
- Permit the use of existing utilization management tools.
- Clarify the start date of the new benefit.
Analysis Prepared by: Lisa Murawski / APPR. / (916) 319-2081
Date of Hearing: July 9, 2019
ASSEMBLY COMMITTEE ON HEALTH
Jim Wood, Chair
SBPCA Bill Id:SB 600
Author:(Portantino) – As Amended Ver:April 30, 2019
SENATE VOTE: 38-0
SUBJECT: Health care coverage: fertility preservation.
SUMMARY: Requires an individual or group health care service plan (health plan) contract or health insurance policy, as specified, to include coverage for standard fertility preservation services when a medically necessary treatment may cause iatrogenic infertility to an enrollee or insured. States that the provisions of this bill are declaratory of existing law. Specifically, this bill:
- Requires a health plan contract or health insurance policy that covers hospital, medical, or surgical expenses to include coverage for medically necessary expenses for standard fertility preservation services when a medically necessary treatment may directly or indirectly cause iatrogenic infertility to an enrollee or insured.
- Defines the following:
- Iatrogenic infertility as an impairment of fertility caused directly or indirectly by surgery, chemotherapy, radiation, or other medical treatment;
- Medical treatment that may directly or indirectly cause iatrogenic infertility as medical treatment with a possible side effect of impaired fertility, as established by the American Society of Clinical Oncology (ASCO) or the American Society for Reproductive Medicine (ASRM); and,
- Standard fertility preservation services as procedures consistent with the established medical practices and professional guidelines published by the ASCO or ASRM.
- Applies this bill to a health plan contract with the Department of Health Care Services (DHCS) when a medically necessary treatment may directly or indirectly cause iatrogenic infertility to a beneficiary.
- Declares that the provisions of this bill does not constitute a change in, but is declaratory of, existing law.
EXISTING LAW:
- Establishes the Department of Managed Health Care (DMHC) to regulate health plans under the Knox-Keene Act and the California Department of Insurance (CDI) to regulate health insurers under the Insurance Code.
- Establishes the Medi-Cal program, administered by DHCS, under which qualified low income individuals are eligible for medical coverage.
- Requires health plans and health insurers providing health coverage in the individual and small group markets to cover, at a minimum, essential health benefits (EHBs), including the 10 EHB benefit categories in the Patient Protection and Affordable Care Act, and consistent with California’s EHB benchmark plan, the Kaiser Foundation Health Plan Small Group HMO 30 plan (Kaiser benchmark), as specified in state law.
- Specifies EHBs in the following 10 categories: ambulatory patient services; emergency services; hospitalization; maternity and newborn care; mental health and substance use disorder services, including behavioral health treatment; prescription drugs; rehabilitative and habilitative services and devices; laboratory services; preventive and wellness services and chronic disease management; and, pediatric oral and vision services.
- Requires health plans to provide basic health care services, including: physician services; hospital inpatient and ambulatory care services; diagnostic laboratory and diagnostic and therapeutic radiologic services; home health services; preventive health services; emergency health care services; and, hospice care.
- Establishes the Independent Medical Review (IMR) and defines a disputed health care service to mean any health care service eligible for coverage and payment under a health plan contract or policy that has been denied, modified, or delayed by a decision of the plan or insurer, or by one of its contracting providers, in whole or in part due to a finding that the service is not medically necessary. Specifies that a decision regarding a disputed health care service relates to the practice of medicine and is not a coverage decision.
- Requires IMR reviewers to determine whether the disputed health care service was medically necessary based on the specific medical needs of the enrollee or insured and any of the following:
- Peer-reviewed scientific and medical evidence regarding the effectiveness of the disputed service;
- Nationally recognized professional standards;
- Expert opinion;
- Generally accepted standards of medical practice; or,
- Treatments that are likely to provide a benefit to a patient for conditions for which other treatments are not clinically efficacious.
- Requires, on and after January 1, 1990, every health care service plan contract or insurance policy that is issued, amended, or renewed that covers hospital, medical, or surgical expenses on a group basis, where the plan is not a health maintenance organization as defined, to offer coverage for the treatment of infertility, except In Vitro Fertilization (IVF), under those terms and conditions as may be agreed upon between the group subscriber and the plan. Requires every plan to communicate the availability of that coverage to all group contractholders and to all prospective group contractholders with whom they are negotiating.
- Defines the following:
- “Infertility” as either: (1) the presence of a demonstrated condition recognized by a licensed physician and surgeon as a cause of infertility; or, (2) the inability to conceive a pregnancy or to carry a pregnancy to a live birth after a year or more of regular sexual relations without contraception.
- “Treatment for infertility” as procedures consistent with established medical practices in the treatment of infertility by licensed physicians and surgeons including, but not limited to, diagnosis, diagnostic tests, medication, surgery, and gamete intrafallopian transfer.
- “IVF” as the laboratory medical procedures involving the actual IVF process.
FISCAL EFFECT: According to the Senate Appropriations Committee:
- Costs of $7,000 (Insurance Fund) in 2019-20, and $20,000 (Insurance Fund) in Fiscal Year 2020-21 for the CDI to review policies and procedures.
- Minor and absorbable costs to the DMHC.
- Indeterminate, significant, ongoing costs (potentially up to $16 million, General Fund (GF)/federal fund or General Fund, entirely) for the DHCS to include fertility preservation services as part of Medi-Cal. The range reflects a high degree of variability in the estimate, specifically: a) considering the additional cost of covering services in the non-managed care population; b) excluding costs associated with services provided pursuant to the Early and Periodic Screening, Diagnostic, and Treatment Services benefit as those are already paid for today; and, c) determining whether DHCS would be able to obtain the standard Federal Medical Assistance Percentage (FMAP) for each population or the enhanced FMAP of 90% for family planning services. If DHCS is unable to obtain these approvals, this bill would be provided as a state-only benefit (all GF) as this bill does not condition implementation of the new benefit upon federal approvals.
COMMENTS:
- PURPOSE OF THIS BILL. According to the author, despite the DMHC repeatedly overturning health plan denials of fertility preservation, denials continually occur and three health plans have blatantly defied the DMHC’s order to pay specific claims. The confusion in coverage forces many patients to forego fertility preservation that they, in fact, have coverage for. They simply do not have time to delay their life-saving cancer treatments to challenge denials of coverage. In the face of these high costs, some patients compromise their treatment decisions in attempts to protect their fertility. Forcing patients into these kinds of decisions may lead to worse medical outcomes.
- BACKGROUND.
- Iatrogenic infertility. According to the California Health Benefit Review Program (CHBRP), iatrogenic infertility is medically induced infertility caused by a medical intervention used to treat a primary disease or condition. Iatrogenic infertility is typically caused by cancer treatments, such as radiation and chemotherapy (gonadotoxic treatments) or surgical removal of reproductive organs. Approximately 90% of iatrogenic infertility is caused by cancer treatment, including services specified by ASCO and ASRM guidelines, this bill would require coverage of: fertility preservation consultation; sperm, oocyte, and embryo cryopreservation; and services as part of or concurrent with cancer treatment for persons likely to experience iatrogenic infertility. CHBRP assumes that enrollees have coverage for fertility preservation consultation and services that are part of or concurrent with cancer treatment; therefore, this report focuses on the impacts of requiring plans and policies to cover sperm, oocyte, and embryo cryopreservation.
- CHBRP analysis. AB 1996 (Thomson), Chapter 795, Statutes of 2002, requests the University of California to assess legislation proposing a mandated benefit or service and prepare a written analysis with relevant data on the medical, economic, and public health impacts of proposed health plan and health insurance benefit mandate legislation. CHBRP was created in response to AB 1996. SB 125 (Ed Hernandez), Chapter 9, Statutes of 2015, added an impact assessment on EHBs, and legislation that impacts health insurance benefit designs, cost sharing, premiums, and other health insurance topics. CHBRP conducted an analysis of a previous version of this bill and this bill currently requires coverage to Medi-Cal beneficiaries. CHBRP confirms that the medical effectiveness findings remains relevant and that the cost and public health impacts projected for the commercial markets and the California Public Employees' Retirement System (CalPERS) remain relevant. CHBRP states in its analysis of this bill the following:
- Impact on expenditures. About 10% of enrollees in the nongrandfathered large group and 100% of enrollees in the Covered California individual markets with coverage for cryopreservation have the same cost-sharing structure as major medical services. CHBRP assumed the cost-sharing structure for cryopreservation would involve a 50% coinsurance, based, for all other enrollees. Cost-sharing impacts (not including premiums) among enrollees using cryopreservation would range from $184 for CalPERS HMO enrollees to $1,051 for enrollees in small group plans. This bill would increase net annual expenditures by total net annual $6,773,000 or total net annual 0.0043% for enrollees with DMHC-regulated plans and CDI-regulated policies. This is due to a $8,263,000 increase in total health insurance premiums paid by employers and enrollees for newly covered benefits, adjusted by a $4,734,000 decrease in enrollee expenses for noncovered benefits.
- Medi-Cal. A prior version of this bill did not include application to Medi-Cal beneficiaries, thus, no CHBRP estimate.
- CalPERS. Premium employer expenditures would increase by $271,000 (0.0087%) for CalPERS enrollees. Enrollees would also see a corresponding increase in employee premiums and out-of-pocket expenses, but a decrease in enrollee expenses for noncovered benefits.
- Number of Uninsured in California. According to CHBRP, this bill would not result in premium increases of more than 1%, and therefore, there would be no measurable impact on the number of uninsured in California.
- EHBs. According to CHBRP, this bill is unlikely to exceed EHBs. DMHC confirmed to CHBRP that under existing law, fertility preservation to address potential iatrogenic infertility is a basic health care service when medically necessary for the enrollee. However, CDI said the current EHB benchmark plan does not include standard fertility preservation services, as defined. CHBRP assumes that DMHC, which also regulates the Kaiser benchmark, the state’s benchmark plan for federal EHBs, is correct in its interpretation of whether this bill would exceed EHBs.
- Medical effectiveness. Recommendations issued by the ASCO in July 2018 indicate that cryopreservation is considered standard practice for fertility preservation in cancer patients. The medical effectiveness review examined whether sperm, oocyte, and embryo cryopreservation services used for fertility perseveration resulted in pregnancy and live births, among other outcomes. There is a preponderance of evidence that sperm, oocyte, and embryo cryopreservation are effective methods of preserving fertility. Other standard fertility preservation services, such as shielding and ovarian transposition, are all covered by insurance as part of standard cancer treatment. Additional fertility preservation services, ovarian suppression with hormones for female breast cancer patients, cryopreservation of ovarian tissue and testicular tissue, testicular suppression with hormones during radiation, and maturation of oocytes outside of the body, are either considered experimental or not broadly recommended.
- Utilization. CHBRP estimates that in the first year postmandate, this bill would result in 792 male and 961 female enrollees with cancer using cryopreservation services. Of the 792 male users postmandate, 136 enrollees would be new users of sperm cryopreservation. The estimated 639 male cryopreservation users at baseline using cryopreservation without coverage would experience financial relief postmandate, because coverage would be available to them. Of the 961 female users postmandate, 516 enrollees would be new users (123 new users of embryo cryopreservation and 392 new users of mature oocyte cryopreservation). A total of 428 female enrollees (102 users of embryo cryopreservation and 326 of mature oocyte cryopreservation) would use cryopreservation with coverage postmandate, whereas they were using the services without coverage at baseline.
- Public health. This bill would likely improve the quality of life by reducing regret about fertility outcomes, dissatisfaction, and distress for the additional 651 enrollees newly using fertility preservation services to prevent iatrogenic infertility. This bill could potentially increase the rate of physician referrals for fertility counseling and preservation by providing coverage for such services and reducing out-of-pocket costs for patients experiencing iatrogenic infertility. In California, females have twice the rate of cancers with treatments causing iatrogenic infertility as males; furthermore, females pay 23 times more for uncovered fertility preservation services than males. Postmandate, this bill would decrease the gender disparity by reducing the financial burden, thereby bringing costs between genders to parity, and reduce the cost consideration from a woman’s decision-making process regarding iatrogenic infertility risk. However, CHBRP estimates that some females would still face greater out-of-pocket expense burdens than males, postmandate, due to differences in costs of sex-specific preservation methods (e.g., more office visits, prescription drug cost, procedure costs) and insurance cost-sharing structures.
- Long-term impacts. Standard fertility preservation services that do not involve cryopreservation, such as ovarian transposition, are covered by insurance as part of standard cancer treatment. Hence, in this analysis CHBRP focused on examining specifically the coverage of cryopreservation of sperm, mature oocytes, and embryos, including all procedures to harvest the materials and storage for one year, among enrollees in DMHC-regulated health plans and CDI-regulated policies in California.
- Impact on expenditures. About 10% of enrollees in the nongrandfathered large group and 100% of enrollees in the Covered California individual markets with coverage for cryopreservation have the same cost-sharing structure as major medical services. CHBRP assumed the cost-sharing structure for cryopreservation would involve a 50% coinsurance, based, for all other enrollees. Cost-sharing impacts (not including premiums) among enrollees using cryopreservation would range from $184 for CalPERS HMO enrollees to $1,051 for enrollees in small group plans. This bill would increase net annual expenditures by total net annual $6,773,000 or total net annual 0.0043% for enrollees with DMHC-regulated plans and CDI-regulated policies. This is due to a $8,263,000 increase in total health insurance premiums paid by employers and enrollees for newly covered benefits, adjusted by a $4,734,000 decrease in enrollee expenses for noncovered benefits.
- Fertility Preservation as a Covered Benefit. According to the DMHC, fertility preservation service is a type of procedure used to help keep a person’s ability to have children. A fertility preservation procedure is done before a medical treatment that may cause infertility, such as radiation therapy or chemotherapy. Examples of fertility preservation procedures include sperm banking, egg freezing, IVF with embryo freezing, and certain types of surgery for cervical and ovarian cancer. All of the above fertility preservation services require consultations (physician services), lab work (diagnostic laboratory services), outpatient surgical procedures (ambulatory care services), and preventative health services, all of which are defined as basic health care services.
- Pending DMHC Case. On April 24, 2019, the DMHC issued an Order to Cease and Desist to one of its health plan licensees. This Order declared that the health plan failed to provide basic health care services as set forth in the Evidence of Coverage (EOC) and acted at variance to its EOCs in denying fertility preservation services under the “Infertility Services” and “Fertility Services” exclusions. The DMHC prohibited the health plan from using any “Infertility Services” or “Fertility Services” exclusion to deny fertility preservation services when medically necessary to prevent iatrogenic infertility; denying fertility preservation services for enrollees at risk of iatrogenic infertility as not covered and/or excluded under an enrollee’s EOC, or on any other basis except for medical necessity; instructing and/or suggesting in any way to its contracted providers and medical groups that fertility preservation services when medically necessary to prevent iatrogenic infertility are not covered; putting any language into an EOC that would indicate that fertility preservation services when medically necessary to prevent iatrogenic infertility are not covered and/or are excluded; and marketing, selling or advertising any fertility preservation riders to large group purchasers.
The health plan subject to the above Order filed a response, indicating that the health plan was under no legal obligation to provide coverage for fertility preservation services to its members, other than those members who purchased the health plan’s optional fertility preservation services rider. The health plan provided support of its position, including, but not limited to: lack of statute that mandates coverage for fertility preservation services; the Legislature introduced bills mandating coverage for fertility preservation services; and, lack of regulation that mandates coverage for fertility preservation services.
According to the DMHC, this enforcement matter is ongoing.
- SUPPORT. According to ASRM, cosponsors of this bill, other conditions requiring similar therapies (sickle cell anemia, lupus, and thalassemia for example) can also compromise fertility, in addition to cancer patients. However, it is not always clear as to whether these procedures are covered insurance options for the majority of patients. The lack of clarity in the coverage is likely that few are (understandably) sophisticated enough to know the difference between fertility preservation and “infertility” coverage. ASRM states that coupled with the short window of opportunity for undergoing these procedures (between diagnosis and commencement of treatment), it is crucial patients know of their options up front. Recent studies find approximately one-third of patients choose less than recommended treatment for their underlying condition in an attempt to preserve their fertility if they cannot obtain fertility preservation services. Despite all health plans denials for cancer patients being overturned by the DMHC, three health plans have defied the regulator and will not pay. As a result, the DMHC recently issued an Order to Cease and Desist against one of the plans (other enforcement actions are still in progress). In the Order, the DMHC states, “the Department has communicated to Kaiser, both verbally and in writing, that fertility preservation services have always been, and continue to be, basic health care services…when medically necessary to prevent iatrogenic infertility.”
- OPPOSITION. The California Chamber of Commerce (CCC) contends that it is unclear what “standard” fertility services include and how many attempts are required under this bill. Additionally, it is unclear whether the bill is focused on medical treatment such as chemotherapy or other cancer related treatment or if the “treatment’ would also include surgery or medication for non-cancer related treatment. Fertility preservation services are very costly, and the broad language of the bill would likely result in significant added costs to all enrollee premiums, not just those who use the services. According to CCC, this bill also prohibits any review of medical necessity by a health plan or insurer. Not only does this eliminate health plan review of this specific issue, it eliminates cost containment measures that benefit all enrollees.
- OPPOSE UNLESS AMENDED. The California Association of Health Plans and the Association of California Life and Health Insurance Companies are requesting the following amendments:
- Remove all references to the retroactivity of the fertility preservation mandate;
- Clarify the definition of medical necessity and define “iatrogenic infertility;”
- Establish a timeframe for storage of reproductive material;
- Require use of evidenced-based standards of care when determining iatrogenic infertility;
- Permit the use of existing utilization management tools; and,
- Clarify the start date of the new benefit.
- RELATED LEGISLATION.
- AB 767 (Wicks) requires Covered California to develop options for the inclusion of IVF coverage as part of, or as supplementary to, coverage currently offered through Covered California, in consultation with stakeholders and by considering specified options. Requires Covered California, on or before July 1, 2020, to report the options to the Legislature and make the report publicly available on its internet website. AB 767 is pending in Senate Health Committee.
- AB 1246 (Limon) requires large group health insurance policies, except certain specialized health insurance policies, issued, amended, or renewed on or after July 1, 2020, to include coverage for medically necessary basic health care services and, to the extent the policy covers prescription drugs, coverage for medically necessary prescription drugs. AB 1246 is pending in Senate Health Committee.
- PREVIOUS LEGISLATION.
- SB 172 (Portantino) of 2017 would have required health plan contracts and health insurance policies to provide coverage for medically necessary expenses for standard fertility preservation services when medical treatment may directly or indirectly cause iatrogenic infertility to an enrollee or insured. SB 172 was held on the Senate Appropriations Committee suspense file.
- AB 912 (Quirk-Silva) of 2013 would have mandated that every large group health plan contract and health insurance policy provide coverage for medically necessary expenses for standard fertility preservation services when a necessary medical treatment may directly or indirectly cause iatrogenic infertility to an enrollee or insured. AB 912 was vetoed by then Governor Brown, who stated in part:
Large group employers already have the ability to negotiate richer benefit packages that meet the needs of their employees. While I understand the desire to preserve fertility where possible, such coverage was not included in the essential health benefits that the Legislature passed just last year for individual and small group coverage. Coverage that goes beyond the essential health benefits is no doubt useful and desirable for many, but we should not consider mandating additional benefits until we implement the comprehensive package of reforms that are required by the federal Affordable Care Act.
- AB 428 (Portantino) of 2011 would have required health plan contracts and health insurance policies to provide coverage for medically necessary expenses for standard fertility preservation services when medical treatment may directly or indirectly cause iatrogenic infertility to an enrollee or insured. AB 428 was held on the Senate Appropriations Committee suspense file.
- POLICY COMMENT. This bill currently includes a provision indicating that this bill does not constitute a change in, but is declaratory of, existing law. The author and sponsors of this bill maintain this bill declares that coverage of fertility preservation is existing law and it is necessary to state this in print as some health plans continue to deny these services. The opposition has argued that this provision creates a dangerous precedent, subverts the legislative process and creates unacceptable liability for health plans which, for years, excluded this coverage with the permission of and approval of regulators. The committee may wish to delete this language as it appears there is some disagreement as to whether or not the services proposed for coverage in this bill are a covered benefit under existing law.
REGISTERED SUPPORT / OPPOSITION:
Support
American Society For Reproductive Medicine (cosponsor)
Alliance For Fertility Preservation (cosponsor)
Fertile Action (cosponsor)
American Cancer Society Cancer Action Network Inc.
American Civil Liberties Union Of California
American Congress Of Obstetricians & Gynecologists - District Ix
American Society Of Clinical Oncology
Association Of Northern California Oncologists
California Chronic Care Coalition
Citizens For Choice
Medical Oncology Association Of Southern California
National Center For Lesbian Rights
Resolve: The National Infertility Association
Teen Cancer America
Triage Cancer
University Of California Los Angeles
Young Survival Coalition
Opposition
America's Health Insurance Plans
California Chamber Of Commerce
Analysis Prepared by: Kristene Mapile / HEALTH / (916) 319-2097
Office of Senate Floor Analyses (916) 651-1520 Fax: (916) 327-4478 | SB 600 |
THIRD READING
Bill No: SB 600
Amended: 4/30/19
SENATE HEALTH COMMITTEE: 8-0, 4/24/19
AYES: Pan, Stone, Durazo, Hurtado, Leyva, Mitchell, Monning, Rubio
NO VOTE RECORDED: Grove
SENATE APPROPRIATIONS COMMITTEE: 4-2, 5/16/19
AYES: Portantino, Bradford, Hill, Wieckowski
NOES: Bates, Jones
SUBJECT: Healthcare coverage: fertility preservation
SOURCE: Alliance for Fertility Preservation
American Society for Reproductive Medicine
Fertile Action
DIGEST:
- This bill requires a health plan contract or health insurance policy that covers hospital, medical, or surgical expenses, and Medi-Cal, to include coverage for medically necessary expenses for standard fertility preservation services when a medically necessary treatment may directly or indirectly cause iatrogenic infertility to an enrollee or insured.
Existing law:
- Establishes the Department of Managed Health Care (DMHC) to regulate health plans under the Knox-Keene Health Care Services Plan Act of 1975; the California Department of Insurance (CDI) to regulate health and other insurers;; and, the Department of Health Care Services (DHCS) to administer the Medi-Cal program. [HSC §1340, et seq., INS §106, et seq., and WIC §14000, et seq.]
- Defines “basic health care services” to include, in part, physician services, including consultation and referral; hospital inpatient services and ambulatory care services; diagnostic laboratory and therapeutic radiologic services; and, emergency health care services, including ambulance and ambulance transport services and out-of-area coverage. Basic health care services includes ambulance and ambulance transport services provided through the 911 emergency response system. [HSC §1345]
- Requires reviews, for purposes of Independent Medical Review (IMR), to determine whether the disputed health care service was medically necessary based on the specific medical needs of the enrollee or insured and any of the following:
- Peer-reviewed scientific and medical evidence regarding the effectiveness of the disputed service;
- Nationally recognized professional standards;
- Expert opinion;
- Generally accepted standards of medical practice; or,
- Treatments that are likely to provide a benefit to a patient for conditions for which other treatments are not clinically efficacious. [HSC §1374.33 and INS §10169.3]
This bill:
- Requires a health plan contract and a health insurance policy that covers hospital, medical, or surgical expenses, and Medi-Cal, to include coverage for medically necessary expenses for standard fertility preservation services when a medically necessary treatment may directly or indirectly cause iatrogenic infertility to an enrollee or insured.
- Defines “Iatrogenic infertility” to mean an impairment of fertility caused directly or indirectly by surgery, chemotherapy, radiation, or other medical treatment.
- States that 1) and 2) above are declaratory of existing law.
Background
- Iatrogenic infertility. Iatrogenic infertility is medically induced infertility caused by a medical intervention used to treat a primary disease or condition. Iatrogenic infertility is typically caused by cancer treatments, such as radiation and chemotherapy (gonadotoxic treatments) or surgical removal of reproductive organs. Less frequently, fertility is compromised by treatments for autoimmune disorders such as systemic lupus erythematosus, rheumatoid arthritis, or Crohn’s disease. Autoimmune conditions sometimes require gonadotoxic or surgical treatments; individuals with gender and sex diversity such as individuals who are transgender may also undergo gonadotoxic treatments. According to data from the California Cancer Registry, more than 8,000 Californians of reproductive age (2,950 males and 5,701 females aged 10 to 44 years), regardless of insurance status, are diagnosed annually with a cancer whose treatments are likely to result in iatrogenic infertility. The increased risk of iatrogenic infertility for women is due to the high incidence of breast cancer.
- California Health Benefits Review Program (CHBRP) analysis. AB 1996 (Thomson, Chapter 795, Statutes of 2002) requests the University of California to assess legislation proposing a mandated benefit or service and prepare a written analysis with relevant data on the medical, economic, and public health impacts of proposed health plan and health insurance benefit mandate legislation. CHBRP was created in response to AB 1996, and reviewed this bill. Because approximately 90% of iatrogenic infertility is caused by cancer treatment, CHBRP focuses on iatrogenic infertility attributable to cancer treatments. CHBRP also indicates that the timeframe for retrieval of embryo, oocyte, or sperm has been documented to range from one to ten years later. This bill does not require coverage for the follow-up assisted reproductive technologies such as artificial insemination, in vitro fertilization, and/or embryo transfer. Key findings include:
- Coverage impacts and enrollees covered. Currently, 0.9% of enrollees with health insurance that would be subject to this bill have coverage for cryopreservation services for sperm, mature oocytes, and embryos. Postmandate, the coverage for cryopreservation would increase to 100%.
- Medical effectiveness. There is a preponderance of evidence that embryo cryopreservation is an effective method of fertility preservation. There is a preponderance of evidence that oocyte cryopreservation is an effective method of fertility preservation measured by three different outcomes: successful thawing of oocytes; successful implantation of embryos; and resulting live births. There is a preponderance of evidence that sperm cryopreservation is an effective method of fertility preservation as measured by pregnancy rates and live births.
- Utilization. CHBRP estimates that in the first year postmandate, this bill would result in 792 male and 961 female enrollees with cancer using cryopreservation services. Of the male users postmandate, 136 enrollees would be new users of sperm cryopreservation. The estimated 639 male cryopreservation users at baseline using cryopreservation without coverage would experience financial relief postmandate, because coverage would be available to them. Of the 961 female users postmandate, 516 enrollees would be new users (123 new users of embryo cryopreservation and 392 new users of mature oocyte cryopreservation). A total of 428 female enrollees (102 users of embryo cryopreservation and 326 of mature oocyte cryopreservation) would use cryopreservation with coverage postmandate, whereas they were using the services without coverage at baseline.
- Coverage impacts and enrollees covered. Currently, 0.9% of enrollees with health insurance that would be subject to this bill have coverage for cryopreservation services for sperm, mature oocytes, and embryos. Postmandate, the coverage for cryopreservation would increase to 100%.
- Impact on expenditures. This bill would increase net annual expenditures by $6,773,000 or 0.0043% for enrollees with DMHC-regulated plans and CDI-regulated policies. This is due to an $8,263,000 increase in total health insurance premiums paid by employers and enrollees for newly covered benefits, adjusted by a $4,734,000 decrease in enrollee expenses for noncovered benefits.
- Public health. This bill likely improves the quality of life by reducing regret about fertility outcomes, dissatisfaction, and distress for the additional 651 enrollees newly using fertility preservation services to prevent iatrogenic infertility. This bill could potentially increase the rate of physician referrals for fertility counseling and preservation by providing coverage for such services and reducing out-of-pocket costs for patients experiencing iatrogenic infertility. In California, females have twice the rate of cancers with treatments causing iatrogenic infertility as males; furthermore, females pay 23 times more for uncovered fertility preservation services than males. Postmandate, this bill decreases the gender disparity by reducing the financial burden, thereby bringing costs between genders to parity, and reduce the cost consideration from a woman’s decision-making process regarding iatrogenic infertility risk. However, CHBRP estimates that some females would still face greater out-of-pocket expense burdens than males, postmandate, due to differences in costs of sex-specific preservation methods (e.g., more office visits, prescription drug cost, and procedure costs) and insurance cost-sharing structures.
- Essential health benefits (EHBs). CHBRP believes this bill is unlikely to exceed EHBs. DMHC confirmed to CHBRP that under existing law, fertility preservation to address potential iatrogenic infertility is a basic health care service within the meaning of the law when medically necessary for the enrollee. However, CDI said the current EHB benchmark plan does not include standard fertility preservation services, as defined. CHBRP assumes that DMHC, which also regulates the Kaiser Foundation Health Plan Small Group HMO 30 plan, the state’s benchmark plan for federal EHBs, is correct in their interpretation of whether this bill would exceed EHBs. CHBRP indicates that DMHC provided a letter to Senator Portantino’s office in response to a request for clarification regarding coverage of fertility preservation, in which DMHC confirmed medically necessary fertility preservation services are covered under the Knox-Keene Act’s requirement that health plans must cover all basic health care services. CHBRP also states that CDI does not currently have a requirement for plans to cover basic health care services. Pursuant to federal regulations it is up to the state to determine which entity should make the determination about whether or not a new benefit exceeds EHB. The state must pay the qualified health plan (QHP) issuer or the enrollee for the cost of any additional benefits. The actual cost of the benefits are determined by each QHP and must be actuarially justified. To date, California has not enacted any benefit mandates that exceed EHB.
- IMRs. The author’s office has provided the Senate Health Committee with copies of five IMR findings that overturned decisions of health plans with respect to reimbursement for fertility preservation services. CHBRP reviewed the state’s IMR determinations and found three determinations related to fertility preservation. The decision most relevant to this bill involved a 33-year old woman who requested embryo cryopreservation following a breast cancer diagnosis. The decision noted that embryo cryopreservation is the best established method of fertility preservation. The IMR decision ruled that this was an appropriate therapy, and the enrollee’s only option to preserve fertility; the health plan’s decision was overturned. Another decision involved an enrollee request for a fertility specialist consultation and potential egg retrieval and use of a surrogate. Partially due to the patient’s age, the IMR deemed that the patient’s request was medically necessary, and the health plan decision was overturned. The third decision involved an enrollee undergoing gender transition (aged 11–20 years) whose parents requested oocyte cryopreservation. The reviewers noted it was not clear whether the patient had expressed a desire to preserve his fertility, and thus, the reviewers deemed that the service was not medically necessary for the enrollees’ treatment. The IMR decision upheld the health plan’s decision.
- DMHC letters. The author’s office provided the Senate Health Committee with a letter from DMHC to a plan enrollee that indicates that the enrollee’s plan covered fertility preservation services as basic health care services that are required under California law, and DMHC directed the plan to reimburse the enrollee for the reasonable cost. The plan declined to comply and the matter was referred to the DMHC Office of Enforcement for further investigation, including possible administrative penalties or fines. Another letter from DMHC provided by the author’s office, dated December 21, 2018, states that fertility preservation is a particular complicated issue, due to its association with standard infertility treatment, which is statutorily exempt as a required basic health care service and often is not covered by health plans except under a separate rider. The letter also states that health plans licensed under the Knox-Keene Act must provide medically necessary fertility preservation services as part of the law’s long standing requirement that health plans cover all basic health care services. DMHC has initiated enforcement action, and DMHC no longer approves plan documentation that purports to exclude medically necessary fertility preservation. DMHC has communicated this to health plans and has conducted individual plan-by-plan conferences to explain DMHC’s position and expectation for compliance. In addition, DMHC does not generally attempt to identify a specific medical standard of care as a covered basic health care service and that by design, basic health care services are flexible as the medical standard evolves. Furthermore, what constitutes medically necessary basic health care services can vary based on the unique circumstances of the patient.
Comments
According to the author, despite DMHC repeatedly overturning health plan denials of fertility preservation, denials continually occur and three health plans have blatantly defied the DMHC’s order to pay specific claims. The confusion in coverage forces many patients to forego fertility preservation that they, in fact, have coverage for. They simply do not have time to delay their life-saving cancer treatments to challenge denials of coverage. In the face of these high costs, some patients compromise their treatment decisions in attempt to protect their fertility. Forcing patients into these kinds of decisions may lead to worse medical outcomes.
FISCAL EFFECT: Appropriation: No Fiscal Com.: Yes Local: No
According to the Senate Appropriations Committee:
- $7,000 (Insurance Fund) in 2019-20, and $20,000 (Insurance Fund) in Fiscal Year (FY) 2020-21 for the CDI to review policies and procedures.
- Minor and absorbable costs to the DMHC.
- Indeterminate, significant, ongoing costs (potentially up to $16 million, General Fund/federal fund or General Fund, entirely) for the DHCS to include fertility preservation services as part of Medi-Cal. The range reflects a high degree of variability in the estimate, specifically: 1) considering the additional cost of covering services in the non-managed care population, 2) excluding costs associated with services provided pursuant to the Early and Periodic Screening, Diagnostic, and Treatment Services benefit as those are already paid for today, and 3) determining whether DHCS would be able to obtain the standard Federal Medical Assistance Percentage (FMAP) for each population or the enhanced FMAP of 90 percent for family planning services. Because the bill does not condition implementation of the new benefit upon federal approvals, if DHCS is unable to obtain these approvals, the bill would be provided as a state-only benefit (all General Fund).
Alliance for Fertility Preservation (co-source)
American Society for Reproductive Medicine (co-source)
Fertile Action (co-source)
American Cancer Society Cancer Action Network
American Civil Liberties Union of California
American College of Obstetricians and Gynecologists District IX
American Society of Clinical Oncology
Association of Northern California Oncologists
California Chronic Care Coalition
California CryoBank
Citizen’s for Choice
Medical Oncology Association of Southern California
Miller Children’s Hospital/ UCLA Dept of Pediatrics Hematology Oncology
National Center for Lesbian Rights
Nevada Citizens for Choice
RESOLVE: The National Infertility Association
Teen Cancer America
Triage Cancer
USC Fertility
Young Survival Coalition
OPPOSITION: (Verified 5/16/19)
America’s Health Insurance Plans
Association of California Life and Health Insurance Companies
California Association of Health Plans
California Chamber of Commerce
ARGUMENTS IN SUPPORT: The American Society for Reproductive Medicine (ASRM) writes, the relatively high out-of-pocket costs (especially for women) for patients paying cash makes treatment unaffordable for many patients if they don’t believe they have coverage. Coupled with the short window of opportunity for undergoing these procedures (between diagnosis and commencement of treatment), it is crucial patients know of their options up front. ASRM finds that some patients choose less than recommended treatment for their underlying condition in an attempt to preserve their fertility if they cannot obtain fertility preservation services. This can lead to worse and more expensive outcomes. While the coverage portion of this bill is declaratory of existing law, ASRM appreciates the addition of a provision regarding medical necessity decisions. Typically the health plan or insurer is charged with making decisions as to whether a particular case meets the criteria of being medically necessary. Due to a pattern of delay and outright refusals to pay claims, even when ordered to by DMHC (regulating HMOs), the step of removing that decision from the health plans and insurers, while drastic, appears necessary under the circumstances. This bill will ensure that all patients who undergo medically necessary treatments such as chemotherapy, radiation, and certain surgeries are also able to access standard fertility preservation treatments more readily in order to protect their future ability to have biologic children. According to the American Cancer Society Action Cancer Network the cost to preserve fertility is not a covered option for the majority of cancer patients, even though fertility loss occurs as a direct consequence of their treatment. As health plans currently cover reconstructive surgery for breast cancer patients, they should similarly reserve the option of fertility preservation for patients undergoing chemotherapy and radiation.
ARGUMENTS IN OPPOSITION: The California Association of Health Plans, the Association of California Life and Health Insurance Companies, and America’s Health Insurance Plans oppose mandate bills that lead to higher premiums, harming affordability and access for small businesses and individual market consumers. Over the past several years, employers have been losing more and more flexibility to set their own benefit designs due to costly state and federal regulations. These mandates will add to those higher health care costs. The California Chamber of Commerce writes that this bill prohibits any review of medical necessity by a health plan and insurer and ignores the rising health care costs and premiums employers and employees continue to face.
Prepared by: Teri Boughton / HEALTH / (916) 651-4111
5/18/19 15:03:44
**** END ****
SENATE COMMITTEE ON APPROPRIATIONS
Senator Anthony Portantino, Chair
2019 - 2020 Regular Session
SB 600 (Portantino) - Health care coverage: fertility preservation
Version: April 30, 2019 | Policy Vote: HEALTH 8 - 0 |
Urgency: No | Mandate: No |
Hearing Date: May 13, 2019 | Consultant: Samantha Lui |
Bill Summary:
Senate Bill 600 would require a health care service plan contract that covers hospital, medical, or surgical expenses, standard fertility preservation services when a medically necessary treatment may cause iatrogenic infertility to a beneficiary. Would add to the standard fertility preservation services, as specified, to the Medi-Cal schedule of benefits.
Fiscal Impact:
- $7,000 (Insurance Fund) in 2019-20, and $20,000 (Insurance Fund) in FY 2020-21 for the Department of Insurance (CDI) to review policies and procedures.
- Minor and absorbable costs to the Department of Managed Health Care (DMHC).
- Indeterminate, significant, ongoing costs (potentially up to $16 million, General Fund/federal fund or General Fund, entirely) for the Department of Health Care Services to include fertility preservation services as part of Medi-Cal. The range reflects a high degree of variability in the estimate, specifically: 1) considering the additional cost of covering services in the non-managed care population, 2) excluding costs associated with services provided pursuant to the Early and Periodic Screening, Diagnostic, and Treatment Services benefit as those are already paid for today, and 3) determining whether DHCS would be able to obtain the standard Federal Medical Assistance Percentage (FMAP) for each population or the enhanced FMAP of 90 percent for family planning services. Because the bill does not condition implementation of the new benefit upon federal approvals, if DHCS is unable to obtain these approvals, the bill would be provided as a state-only benefit (all General Fund). For more detail, please see Staff Comments.
Background:
Under existing law, the DMHC licenses and regulates health plans, and the CDI regulates health insurers. Every group health plan contract and insurance policy issued, amended, or renewed on or after January 1, 2017, must include a minimum coverage for essential health benefits, including basic health services:
- Physician services, including consultation and referral;
- Hospital inpatient services and ambulatory care services;
- Diagnostic laboratory and therapeutic radiologic services;
- Home health services;
- Preventive health services;
- Emergency health care services, including ambulance and ambulance transport services and out-of-area coverage. Basic health care services includes ambulance and ambulance transport services provided through the 911 emergency response system; and,
- Hospice care, as specified.
Iatrogenic infertility is medically induced infertility caused by a medical intervention used to treat a primary disease or condition. Iatrogenic infertility is typically caused by cancer treatments, such as radiation and some chemotherapy or surgical removal of reproductive organs. Less frequently, fertility is compromised by treatments for autoimmune disorders such as systemic lupus erythematosus, rheumatoid arthritis, or Crohn’s disease. Approximately 90% of iatrogenic infertility is caused by cancer treatment.
According to the CHBRP analysis, DMHC confirmed to CHBRP that under existing law, fertility preservation to address potential iatrogenic infertility is a basic health care service within the meaning of the law when medically necessary for the enrollee. However, CDI said the current EHB benchmark plan does not include standard fertility preservation services, as defined. This bill does not require coverage for the follow-up assisted reproductive technologies such as artificial insemination, in vitro fertilization, and/or embryo transfer.
Proposed Law:
The bill includes the following provisions, among others:
- Clarifies that an individual or group health care service plan contract or insurance policy that covers hospital, medical, or surgical expenses includes coverage for standard fertility preservation services, when a medically necessary treatment may cause iatrogenic infertility to an enrollee or insured.
- Provides that its provisions are declaratory of existing law.
- Defines “iatrogenic infertility” is a fertility impairment caused directly or indirectly by surgery, chemotherapy, radiation, or other medical treatment.
- Defines standard fertility preservation services as procedures consistent with the American Society of Clinical Oncology or the American Society for Reproductive Medicine's guidelines.
Related Legislation:
AB 767 (Wicks) would require coverage for in vitro fertilization, as a treatment of infertility, and mature oocyte cryopreservation. AB 767 is in the Assembly Appropriations Committee.
Staff Comments:
The Senate Health Committee analysis discussed how California’s existing coverage mandates, including EHB, provide comprehensive benefit coverage. The Legislature is currently deliberating several measures whose cumulative impact, if enacted, could affect the marketplace and affordability, broadly.
The April 17, 2019, California Health Benefits Review Program (CHBRP) fiscal analysis did not reflect the bill’s recent amendment to include standard fertility preservation to the schedule of Medi-Cal benefits. As such, the bill’s impacts are higher than the original estimate. CHBRP estimated the bill would increase net annual expenditures by $6.8 million for enrollees with DMHC-regulated plans and CDI-regulated policies, due to an $8.3 million increase in total health insurance premiums paid by employers and enrollees for newly covered benefits, adjusted by a $4.7 million decrease in enrollee expenses for noncovered benefits. CHBRP estimates that in the first year postmandate, this bill would result in 792 male and 961 female enrollees with cancer using cryopreservation services.
In an effort to provide a sense of the potential magnitude of the covering fertility preservation services, DHCS developed a limited estimate in the table below. This estimate is based on DHCS review of several studies and show a wide range of variation (from 0.0041 percent to 0.05 percent) of health insurers’ premiums. DHCS applied these percentages to total estimated Medi-Cal managed care base expenditures in the November 2018 Medi-Cal Local Assistance Estimate, and assumed DHCS is able to obtain all necessary federal approvals to claim federal financial participation. Staff notes the same variables outlined in the Fiscal Impact apply, here.
Potential Medi-Cal Managed Care Impacts of SB 600 |
Assumed % Increase in Expenditures | Total Fund | General Fund (GF) (assume standard FMAP) | GF (assume 90 percent FMAP) |
0.0041% | $1,361,000 | $436,000 | $136,000 |
0.0100% | $3,319,000 | $1,063,000 | $332,000 |
0.0400% | $13,276,000 | $4,251,000 | $1,328,000 |
0.0500% | $16,595,000 | $5,314,000 | $1,660,000 |
-- END --
SENATE COMMITTEE ON HEALTH
Senator Dr. Richard Pan, Chair
BILL NO: SB 600
AUTHOR: | Portantino | ||
VERSION: | February 22, 2019 | ||
HEARING DATE: | April 24, 2019 | ||
CONSULTANT: | Teri Boughton | ||
SUBJECT: Healthcare coverage: fertility preservation
SUMMARY:
- Requires an individual or group health plan contract or health insurance policy that covers hospital, medical, or surgical expenses to include coverage for medically necessary expenses for standard fertility preservation services when a medically necessary treatment may directly or indirectly cause iatrogenic infertility to an enrollee or insured, and deems standard fertility preservation services medically necessary when a provider of treatment of a medical condition authorized by a health plan or health insurance policy states that there is a substantial likelihood that the treatment may directly or indirectly cause iatrogenic infertility.
Existing law:
- Establishes the Department of Managed Health Care (DMHC) to regulate health plans under the Knox-Keene Health Care Services Plan Act of 1975; the California Department of Insurance (CDI) to regulate health and other insurers; Covered California as California’s health benefit exchange for individual and small business purchasers as authorized under the federal Patient Protection and Affordable Care Act (ACA); and, the Department of Health Care Services (DHCS) to administer the Medi-Cal program. [HSC §1340, et seq., INS §106, et seq., GOV §100500 -100522, and WIC §14000, et seq.]
- Establishes as California's essential health benefits (EHBs) benchmark the Kaiser Small Group Health Maintenance Organization, existing California mandates (including medically necessary basic health care services), and ten ACA mandated benefits. Requires non-grandfathered individual and small group plan contracts and insurance policies to cover these EHBs. [HSC §1367.005 and INS §10112.27]
- Requires health plan contracts and health insurance policies to offer group coverage for the treatment of infertility, except in vitro fertilization, as defined. [HSC §1374.55 and INS §10119.6]
- Defines “basic health care services” as all of the following:
- Physician services, including consultation and referral;
- Hospital inpatient services and ambulatory care services;
- Diagnostic laboratory and therapeutic radiologic services;
- Home health services;
- Preventive health services;
- Emergency health care services, including ambulance and ambulance transport services and out-of-area coverage. Basic health care services includes ambulance and ambulance transport services provided through the 911 emergency response system; and,
- Hospice care, as specified.
- Requires reviews, for purposes of Independent Medical Review (IMR), to determine whether the disputed health care service was medically necessary based on the specific medical needs of the enrollee or insured and any of the following:
- Peer-reviewed scientific and medical evidence regarding the effectiveness of the disputed service;
- Nationally recognized professional standards;
- Expert opinion;
- Generally accepted standards of medical practice; or,
- Treatments that are likely to provide a benefit to a patient for conditions for which other treatments are not clinically efficacious. [HSC §1374.33 and INS §10169.3]
This bill:
- Requires an individual or group health plan contract and a health insurance policy that covers hospital, medical, or surgical expenses to include coverage for medically necessary expenses for standard fertility preservation services when a medically necessary treatment may directly or indirectly cause iatrogenic infertility to an enrollee or insured.
- Defines:
- “Iatrogenic infertility” to mean an impairment of fertility caused directly or indirectly by surgery, chemotherapy, radiation, or other medical treatment.
- “Medical treatment that may directly or indirectly cause iatrogenic infertility” to mean medical treatment with a possible side effect of impaired fertility, as established by the American Society of Clinical Oncology (ASCO), the American Society for Reproductive Medicine (ASRM), or other reputable professional association or organization.
- “Standard fertility preservation services” to mean procedures consistent with the established medical practices and professional guidelines published by ASCO, ASRM, or other reputable professional medical organization.
- “Medical treatment that may directly or indirectly cause iatrogenic infertility” to mean medical treatment with a possible side effect of impaired fertility, as established by the American Society of Clinical Oncology (ASCO), the American Society for Reproductive Medicine (ASRM), or other reputable professional association or organization.
- States that 1) and 2) above are declaratory of existing law.
- Deems standard fertility preservation services medically necessary when a provider of treatment of a medical condition authorized by a health plan or health insurance policy states that there is a substantial likelihood that the treatment may directly or indirectly cause iatrogenic infertility to the enrollee or insured, and prohibits a plan or insurer from denying coverage for those services based on medical necessity.
FISCAL EFFECT:
This bill has not been analyzed by a fiscal committee.
COMMENTS:
- Author’s statement. According to the author, despite DMHC repeatedly overturning health plan denials of fertility preservation, denials continually occur and three health plans have blatantly defied the DMHC’s order to pay specific claims. The confusion in coverage forces many patients to forego fertility preservation that they, in fact, have coverage for. They simply do not have time to delay their life-saving cancer treatments to challenge denials of coverage. In the face of these high costs, some patients compromise their treatment decisions in attempt to protect their fertility. Forcing patients into these kinds of decisions may lead to worse medical outcomes.
- Iatrogenic infertility. Iatrogenic infertility is medically induced infertility caused by a medical intervention used to treat a primary disease or condition. Iatrogenic infertility is typically caused by cancer treatments, such as radiation and chemotherapy (gonadotoxic treatments) or surgical removal of reproductive organs. Less frequently, fertility is
compromised by treatments for autoimmune disorders such as systemic lupus erythematosus, rheumatoid arthritis, or Crohn’s disease. Autoimmune conditions sometimes require gonadotoxic or surgical treatments; individuals with gender and sex diversity such as individuals who are transgender may also undergo gonadotoxic treatments. According to data from the California Cancer Registry, more than 8,000 Californians of reproductive age (2,950 males and 5,701 females aged 10 to 44 years), regardless of insurance status, are diagnosed annually with a cancer whose treatments are likely to result in iatrogenic infertility. The increased risk of iatrogenic infertility for women is due to the high incidence of breast cancer.
- California Health Benefits Review Program (CHBRP) analysis. AB 1996 (Thomson, Chapter 795, Statutes of 2002) requests the University of California to assess legislation proposing a mandated benefit or service and prepare a written analysis with relevant data on the medical, economic, and public health impacts of proposed health plan and health insurance benefit mandate legislation. CHBRP was created in response to AB 1996, and reviewed this bill. Because approximately 90% of iatrogenic infertility is caused by cancer treatment, CHBRP focuses on iatrogenic infertility attributable to cancer treatments. CHBRP also indicates that the timeframe for retrieval of embryo, oocyte, or sperm has been documented to range from one to ten years later. This bill does not require coverage for the follow-up assisted reproductive technologies such as artificial insemination, in vitro fertilization, and/or embryo transfer. Key findings include:
- Coverage impacts and enrollees covered. Currently, 0.9% of enrollees with health insurance that would be subject to this bill have coverage for cryopreservation services for sperm, mature oocytes, and embryos. Postmandate, the coverage for cryopreservation would increase to 100%.
- Medical effectiveness. There is a preponderance of evidence that embryo cryopreservation is an effective method of fertility preservation. There is a preponderance of evidence that oocyte cryopreservation is an effective method of fertility preservation measured by three different outcomes: successful thawing of oocytes; successful implantation of embryos; and resulting live births. There is a preponderance of evidence that sperm cryopreservation is an effective method of fertility preservation as measured by pregnancy rates and live births.
- Utilization. CHBRP estimates that in the first year postmandate, this bill would result in 792 male and 961 female enrollees with cancer using cryopreservation services. Of the male users postmandate, 136 enrollees would be new users of sperm cryopreservation. The estimated 639 male cryopreservation users at baseline using cryopreservation without coverage would experience financial relief postmandate, because coverage would be available to them. Of the 961 female users postmandate, 516 enrollees would be new users (123 new users of embryo cryopreservation and 392 new users of mature oocyte cryopreservation). A total of 428 female enrollees (102 users of embryo cryopreservation and 326 of mature oocyte cryopreservation) would use cryopreservation with coverage postmandate, whereas they were using the services without coverage at baseline.
- Coverage impacts and enrollees covered. Currently, 0.9% of enrollees with health insurance that would be subject to this bill have coverage for cryopreservation services for sperm, mature oocytes, and embryos. Postmandate, the coverage for cryopreservation would increase to 100%.
- Medi-Cal. This bill specifies applicability to “group and individual” health insurance, which means it would not be applicable to the benefit coverage of the 7.6 million Medi-Cal beneficiaries enrolled in DMHC-regulated plans.
- Impact on expenditures. This bill would increase net annual expenditures by $6,773,000 or 0.0043% for enrollees with DMHC-regulated plans and CDI-regulated policies. This is due to an $8,263,000 increase in total health insurance premiums paid by employers and enrollees for newly covered benefits, adjusted by a $4,734,000 decrease in enrollee expenses for noncovered benefits.
- Public health. This bill would likely improve the quality of life by reducing regret about fertility outcomes, dissatisfaction, and distress for the additional 651 enrollees newly using fertility preservation services to prevent iatrogenic infertility. This bill could potentially increase the rate of physician referrals for fertility counseling and preservation by providing coverage for such services and reducing out-of-pocket costs for patients experiencing iatrogenic infertility. In California, females have twice the rate of cancers with treatments causing iatrogenic infertility as males; furthermore, females pay 23 times more for uncovered fertility preservation services than males. Postmandate, this bill would decrease the gender disparity by reducing the financial burden, thereby bringing costs between genders to parity, and reduce the cost consideration from a woman’s decision-making process regarding iatrogenic infertility risk. However, CHBRP estimates that some females would still face greater out-of-pocket expense burdens than males, postmandate, due to differences in costs of sex-specific preservation methods (e.g., more office visits, prescription drug cost, and procedure costs) and insurance cost-sharing structures.
- Essential health benefits. CHBRP believes this bill is unlikely to exceed EHBs. DMHC confirmed to CHBRP that under existing law, fertility preservation to address potential iatrogenic infertility is a basic health care service within the meaning of the law when medically necessary for the enrollee. However, CDI said the current EHB benchmark plan does not include standard fertility preservation services, as defined. CHBRP assumes that DMHC, which also regulates the Kaiser Foundation Health Plan Small Group HMO 30 plan, the state’s benchmark plan for federal EHBs, is correct in their interpretation of whether this bill would exceed EHBs. CHBRP indicates that DMHC provided a letter to Senator Portantino’s office in response to a request for clarification regarding coverage of fertility preservation, in which DMHC confirmed medically necessary fertility preservation services are covered under the Knox-Keene Act’s requirement that health plans must cover all basic health care services. CHBRP also states that CDI does not currently have a requirement for plans to cover basic health care services. Pursuant to federal regulations it is up to the state to determine which entity should make the determination about whether or not a new benefit exceeds EHB. The state must pay the qualified health plan (QHP) issuer or the enrollee for the cost of any additional benefits. The actual cost of the benefits are determined by each QHP and must be actuarially justified. To date, California has not enacted any benefit mandates that exceed EHB.
- IMRs. The author’s office has provided the Committee with copies of five IMR findings that overturned decisions of health plans with respect to reimbursement for fertility preservation services. CHBRP reviewed the state’s IMR determinations and found three determinations related to fertility preservation. The decision most relevant to this bill involved a 33-year old woman who requested embryo cryopreservation following a breast cancer diagnosis. The decision noted that embryo cryopreservation is the best established method of fertility preservation. The IMR decision ruled that this was an appropriate therapy, and the enrollee’s only option to preserve fertility; the health plan’s decision was overturned. Another decision involved an enrollee request for a fertility specialist consultation and potential egg retrieval and use of a surrogate. Partially due to the patient’s age, the IMR deemed that the patient’s request was medically necessary, and the health plan decision was overturned. The third decision involved an enrollee undergoing gender transition (aged 11–20 years) whose parents requested oocyte cryopreservation. The reviewers noted it was not clear whether the patient had expressed a desire to preserve his fertility, and thus, the reviewers deemed that the service was not medically necessary for the enrollees’ treatment. The IMR decision upheld the health plan’s decision.
- DMHC letters. The author’s office provided the Committee with a letter from DMHC to a plan enrollee that indicates that the enrollee’s plan covered fertility preservation services as basic health care services that are required under California law, and DMHC directed the plan to reimburse the enrollee for the reasonable cost. The plan declined to comply and the matter was referred to the DMHC Office of Enforcement for further investigation, including possible administrative penalties or fines. Another letter from DMHC provided by the author’s office, dated December 21, 2018, states that fertility preservation is a particular complicated issue, due to its association with standard infertility treatment, which is statutorily exempt as a required basic health care service and often is not covered by health plans except under a separate rider. The letter also states that health plans licensed under the Knox-Keene Act must provide medically necessary fertility preservation services as part of the law’s long standing requirement that health plans cover all basic health care services. DMHC has initiated enforcement action, and DMHC no longer approves plan documentation that purports to exclude medically necessary fertility preservation. DMHC has communicated this to health plans and has conducted individual plan-by-plan conferences to explain DMHC’s position and expectation for compliance. In addition, DMHC does not generally attempt to identify a specific medical standard of care as a covered basic health care service and that by design, basic health care services are flexible as the medical standard evolves. Furthermore, what constitutes medically necessary basic health care services can vary based on the unique circumstances of the patient.
- Related legislation. SB 11 (Beall) requires on-formulary, lowest tier coverage of prescription medications approved by the FDA for treatment of substance use disorders. SB 11 is set for hearing on April 24, 2019 in this Committee.
SB 159 (Wiener) authorizes a pharmacist to furnish preexposure prophylaxis (PrEP) and postexposure prophylaxis (PEP), in specified amounts, if the pharmacist completes a training program approved by the Board of Pharmacy and complies with specified requirements, such as assessing a patient and providing a patient with counseling and tests. Prohibits plans and insurers from subjecting combination antiretroviral drug treatments that are medically necessary for the prevention of AIDS/HIV, including PrEP and PEP, to prior authorization or step therapy, and expands the Medi-Cal schedule of benefits to include PrEP and PEP as pharmacist services. SB 159 is set for hearing on April 24, 2019 in this Committee.
SB 163 (Portantino) expands the definition of behavioral health treatment (BHT) and expands the provider qualifications to include more provider types that can provide BHT under the mandate that health plans and insurers cover BHT for pervasive developmental disorder or autism. Prohibits the setting, location, or time of treatment recommended by a qualified autism services provider from being used as the only reason to deny or reduce coverage for medically necessary services. Requires the setting to be consistent with the standard of care for BHT. SB 163 passed the Senate Health Committee by a vote of 8-0 on April 3, 2019.
SB 583(Jackson) expands coverage for clinical trials to include a clinical trial relating to the prevention, detection, or treatment of a life-threatening disease or condition, as defined, and includes a trial funded by, among others, a qualified nongovernmental research entity. SB 583 is set for hearing in this Committee on April 24, 2019.
SB 746 (Bates) requires that coverage for chemotherapy or radiation therapy for the treatment of cancer includes coverage for anticancer medical devices. SB 746 is set for hearing in this Committee on April 24, 2019.
AB 598 (Bloom) requires coverage for hearing aids, as defined, for an enrollee or insured under 18 years of age, as specified. AB 598 is set for hearing in the Assembly Health Committee on April 23, 2019.
AB 651 (Grayson) requires when an the enrollee, insured, or subscriber receives covered services from a noncontracting air ambulance provider, to pay no more than the same cost sharing that the enrollee, insured, or subscriber would pay for the same covered services received from a contracting air ambulance provider. AB 651 is set for hearing in the Assembly Health Committee on April 23, 2019.
AB 744 (Aguiar-Curry) requires reimbursement of a healthcare provider for the diagnosis, consultation, or treatment of an enrollee, subscriber, insured, or policyholder delivered through telehealth services on the same basis and to the same extent as the same service provided through in-person diagnosis, consultation, or treatment. AB 744 is set for hearing in the Assembly Health Committee on April 23, 2019.
AB 767(Wicks) requires coverage for in vitro fertilization, as a treatment of infertility, and mature oocyte cryopreservation. AB 767 is set for hearing in the Assembly Health Committee on April 23, 2019.
AB 993 allows health plans to include HIV specialists as eligible primary care providers (PCPs), if the provider requests PCP status and meets the health insurer’s eligibility criteria. AB 993 passed the Assembly Health Committee by a vote of 15-0 on April 9, 2019.
AB 1246 (Limon) requires large group health insurance policies to include coverage for medically necessary basic health care services and, to the extent the policy covers prescription drugs, coverage for medically necessary prescription drugs. AB 1246 passed the Assembly Health Committee by a vote of 11-3 on April 9, 2019.
AB 1611(Chiu) requires that if an enrollee or insured receives covered services from a noncontracting hospital, the enrollee or insured is prohibited from paying more than the same cost sharing that the enrollee or insured would pay for the same covered services received from a contracting hospital. AB 1611 is set for hearing in the Assembly Health Committee on April 23, 2019.
AB 1676 (Maienschein) requires coverage for a telehealth consultation program that provides providers who treat children and pregnant and postpartum persons with access to a psychiatrist, as specified, in order to more quickly diagnose and treat children and pregnant and postpartum persons suffering from mental illness. AB 1676 is set for hearing in the Assembly Health Committee on April 23, 2019.
- Prior legislation. SB 172 (Portantino of 2017) would have required health plan contracts and health insurance policies to provide coverage for medically necessary expenses for standard fertility preservation services when medical treatment may directly or indirectly cause iatrogenic infertility to an enrollee or insured. SB 172 was held on the Senate Appropriations Committee suspense file.
AB 912 (Quirk-Silva of 2013) would have mandated that every large group health plan contract and health insurance policy to provide coverage for medically necessary expenses for standard fertility preservation services when a necessary medical treatment may directly or indirectly cause iatrogenic infertility to an enrollee or insured. AB 912 was vetoed by Governor Brown, who stated in part:
Large group employers already have the ability to negotiate richer benefit packages that meet the needs of their employees. While I understand the desire to preserve fertility where possible, such coverage was not included in the essential health benefits that the Legislature passed just last year for individual and small group coverage. Coverage that goes beyond the essential health benefits is no doubt useful and desirable for many, but we should not consider mandating additional benefits until we implement the comprehensive package of reforms that are required by the [ACA].
AB 428 (Portantino of 2011) would have required health plan contracts and health insurance policies to provide coverage for medically necessary expenses for standard fertility preservation services when medical treatment may directly or indirectly cause iatrogenic infertility to an enrollee or insured. AB 428 was held on the Senate Appropriations Committee suspense file.
- Support. ASRM writes, the relatively high out-of-pocket costs (especially for women) for patients paying cash makes treatment unaffordable for many patients if they don’t believe they have coverage. Coupled with the short window of opportunity for undergoing these procedures (between diagnosis and commencement of treatment), it is crucial patients know of their options up front. ASRM finds that some patients choose less than recommended treatment for their underlying condition in an attempt to preserve their fertility if they cannot obtain fertility preservation services. This can lead to worse and more expensive outcomes. While the coverage portion of this bill is declaratory of existing law, ASRM appreciates the addition of a provision regarding medical necessity decisions. Typically the health plan or insurer is charged with making decisions as to whether a particular case meets the criteria of being medically necessary. Due to a pattern of delay and outright refusals to pay claims, even when ordered to by DMHC (regulating HMOs), the step of removing that decision from the health plans and insurers, while drastic, appears necessary under the circumstances. This bill will ensure that all patients who undergo medically necessary treatments such as chemotherapy, radiation, and certain surgeries are also able to access standard fertility preservation treatments more readily in order to protect their future ability to have biologic children. According to the American Cancer Action Network the cost to preserve fertility is not a covered option for the majority of cancer patients, even though fertility loss occurs as a direct consequence of their treatment. As health plans currently cover reconstructive surgery for breast cancer patients, they should similarly reserve the option of fertility preservation for patients undergoing chemotherapy and radiation.
- Opposition. The California Association of Health Plans, the Association of California Life and Health Insurance Companies, and America’s Health Insurance Plans oppose mandate bills that lead to higher premiums, harming affordability and access for small businesses and individual market consumers. Over the past several years, employers have been losing more and more flexibility to set their own benefit designs due to costly state and federal regulations. These mandates will add to those higher health care costs. The California Chamber of Commerce writes that this bill prohibits any review of medical necessity by a health plan and insurer and ignores the rising health care costs and premiums employers and employees continue to face.
- Policy Comment.
- Clarification warranted. Even DMHC has suggested there has been and continues to be confusion about coverage for fertility preservation for iatrogenic infertility. Additionally, CDI does not have the basic health services requirement to the same extent as DMHC. Therefore, it seems a clarification in this case is necessary.
- Deemed medically necessary. Sections two and four of the bill deem standard fertility preservation services medically necessary when a provider of treatment states there is substantial likelihood that treatment may directly or indirectly cause iatrogenic infertility. This is beyond a clarification of what is believed to be the law, and could go beyond the standards established by the ASRM or ASCO.
- Multiple Mandates and Market uncertainty. California’s existing coverage mandates including EHB already provide very comprehensive benefit coverage. The Committee will be hearing multiple bills this year that will have small to large relative impacts on health insurance premiums. This bill is one of six Senate Bills to be considered. While many policy arguments can be made to advance all of these bills, committee members may also wish to consider the cumulative effect of these bills and the tradeoffs associated with increasing health insurance premiums in the context of the already high cost of health insurance, another potential restructuring of health insurance markets nationally and in California because of actions taking place at the federal level to repeal the ACA, and in consideration of the Governor’s budget proposal, and other legislation, to provide state financial assistance and to require Californians to purchase health insurance.
- Amendments.
- The author and sponsor request the committee adopt an amendment make the provisions of this bill applicable to Medi-Cal managed care contracts.
- The committee may wish to request amendments to narrow this bill to sections one and three. Additionally, including other unnamed “reputable professional associations or organizations” may allow for unanticipated expansion of this bill. The committee may wish to limit this bill to the treatments, practices and guidelines established by the ASRM and ASCO.
- The author and sponsor request the committee adopt an amendment make the provisions of this bill applicable to Medi-Cal managed care contracts.
- Clarification warranted. Even DMHC has suggested there has been and continues to be confusion about coverage for fertility preservation for iatrogenic infertility. Additionally, CDI does not have the basic health services requirement to the same extent as DMHC. Therefore, it seems a clarification in this case is necessary.
SUPPORT AND OPPOSITION:
Support: American Society for Reproductive Medicine (co-sponsor)
Alliance for Fertility Preservation (co-sponsor)
Fertile Action (co-sponsor)
American Cancer Society Cancer Action Network
American Civil Liberties Union of California
American College of Obstetricians and Gynecologists District IX
American Society of Clinical Oncology
Association of Northern California Oncologists
Citizen’s for Choice
Medical Oncology Association of Southern California
Miller Children’s Hospital/ UCLA Dept of Pediatrics Hematology Oncology
National Center for Lesbian Rights
Oppose: America’s Health Insurance Plans
Association of California Life and Health Insurance Companies
California Association of Health Plans
California Chamber of Commerce
-- END --
Bill Author
Bill Co-Author(s):